Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Clinics and Research in Hepatology and Gastroenterology Année : 2018

Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy

Résumé

Presence of anti-E1E2 antibodies was previously associated with spontaneous cure of hepatitis C virus (HCV) and predictive before treatment of a sustained virological response (SVR) to bi- or tri-therapy in naïve or experienced patients, regardless of HCV genotype. We investigated the impact of anti-E1E2 seroprevalence at baseline on treatment response in patients receiving direct-acting antiviral (DAA) therapy.
Fichier non déposé

Dates et versions

hal-02059875 , version 1 (07-03-2019)

Identifiants

Citer

Victor Virlogeux, Pascale Berthillon, Isabelle Bordes, Sylvie Larrat, Stéphanie Crouy, et al.. Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy. Clinics and Research in Hepatology and Gastroenterology, 2018, 42 (4), pp.313-318. ⟨10.1016/j.clinre.2018.02.002⟩. ⟨hal-02059875⟩
69 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More